The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression

Abstract

Tyrosine kinase signalling within cancer cells is central to the establishment of an immunosuppressive microenvironment. Although tyrosine kinase inhibitors act, in part, to augment adaptive immunity, the increased heterogeneity and functional redundancy of the tyrosine kinome is a hurdle to achieving durable responses to immunotherapies. We previously identified the Shc1 (ShcA) scaffold, a central regulator of tyrosine kinase signalling, as essential for promoting breast cancer immune suppression. Herein we show that the ShcA pathway simultaneously activates STAT3 immunosuppressive signals and impairs STAT1-driven immune surveillance in breast cancer cells. Impaired Y239/Y240-ShcA phosphorylation selectively reduces STAT3 activation in breast tumours, profoundly sensitizing them to immune checkpoint inhibitors and tumour vaccines. Finally, the ability of diminished tyrosine kinase signalling to initiate STAT1-driven immune surveillance can be overcome by compensatory STAT3 hyperactivation in breast tumours. Our data indicate that inhibition of pY239/240-ShcA-dependent STAT3 signalling may represent an attractive therapeutic strategy to sensitize breast tumours to multiple immunotherapies.

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response

“…In our classification, the absence of DNA variant evidence could be a limitation, but tumorigenic functions by variants could be inferred from transcriptional consensus change (21,26). For example, BRCAness by BRCA1/2 (54). Our pathogenic BRCA1/2 enrichment in SL was consistent with Lehmann's identification in BL1 and BL2 (5).…”

Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma

“…To investigate in detail how LGALS1 was involved in the GBM immunosuppressive microenvironment, we undertook big data analysis and evaluated the immunosuppressive cytokines known to be tightly associated with immunosuppressive microenvironment. LGASL1 was positively associated with immunosuppressive genes: LGALS3 , impairing function of human CD4 and CD8 tumour‐infiltrating lymphocytes, SWAP70 restricting spontaneous maturation of dendritic cells (DCs), CHI3L1 secreted by M2 macrophages promoting gastric and breast cancer metastasis, CCL2, SERPING1 inhibiting activation of the complement system, ANXA1 regulating TGF‐β signalling and promoting metastasis formation of basal‐like breast cancer cells, SHC1 promoting breast cancer immune suppression through STAT1 and STAT3, TIMP1 having a liner relationship with CD11b + Gr1+ myeloid cells and CD4 + CD25 + FOXP3+ Tregs, ICAM1 critical for mesenchymal stem cell (MSC)‐mediated immunosuppression, LTBP1 required for an adequate TGF‐β function, CD163, MR1 resulting in a relative increase in Tregs and TNFRSF1A required for STAT3 phosphorylation and MDSC accumulation . We also found that the expression of VEGFA, CCL2 and TGF‐β were restrained in the LGALS1 knockdown group.…”

Myeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy

“…STAT3 also have indirect effects on MDSCs differentiation. For example, STAT3 may promote the activation and recruitment of MDSCs by regulating expression of factors like APP . In animal models of sepsis, binding with cytokine receptor gpl30, a ligand‐binding chain (IL‐6R) and a nonligand‐binding signal transducer, IL‐6 in hepatocyte can up‐regulate serum amyloid protein A (SAA) and chemotactic factor CXCL1, leading to the accumulation of MDSCs in spleen .…”